CELULARITY IMPACT
LIVE

Serial Number

97265928

Owner

CELULARITY, INC.

Attorney

Camille M. Miller

First Use Date

Mar 29, 2019

Filing Date

Feb 14, 2022

Add to watchlist:

No watchlists yet
View on USPTO

CELULARITY IMPACT Trademark

Serial Number: 97265928 • Registration: 6782541

CELULARITY IMPACT is a trademark filed by CELULARITY, INC. on February 14, 2022. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

CELULARITY, INC. (50 trademarks)

33 TECHNOLOGY DRIVE
WARREN, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

February 14, 2022

Registration Date

July 5, 2022

First Use Anywhere

March 29, 2019

First Use in Commerce

March 29, 2019

Published for Opposition

April 19, 2022

Goods & Services

Manufacturing services of biopharmaceuticals and gene and cell therapy products, namely, genetically engineered tissues for others; manufacturing services for others in the fields of mammalian cell banks, plasmids, purified mitochondria, cell lysates; production of cells for others; custom manufacturing of cells for others; advanced cell manufacturing for others; manufacturing process consulting

Research, development and testing services in the fields of genomics, biotechnology and pharmaceuticals, namely, collection, testing, processing, preservation, storage and retrieval of cells and biological tissue, namely, blood, stem cells, umbilical cords, umbilical cord blood, and placental tissue; laboratory research services in the field of genomics, biotechnology and pharmaceuticals consisting of collection, testing, processing, preservation, storage and retrieval of bioengineered cells, human allograft tissue made from human umbilical cords and human placentas, human amniotic membrane and human chorionic membrane, human collagen and extracellular matrix compositions; providing a website featuring information in the field of medical research relating to banking stem cells and cord blood banking; biosourcing of clinically accessible, immune-tolerant human stem and progenitor and other postpartum placenta-derived cell populations and tissues for medical research; scientific and technological services, namely, scientific research, analysis, and testing in the field of genomics, biotechnology, and pharmaceuticals; medical research to find methods to restore the structure and function of damaged or diseased tissues and organs, including wound care, reconstructive medicine, whole organ and tissue regeneration and renewal; medical research regarding emergent cell therapies; medical research regarding allogeneic immunotherapy; providing on-line information, news and commentary in the field of medical research relating to the foregoing; research, development and testing services for others in the fields of genomics, biotechnology and pharmaceuticals

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 5, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Jul 5, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 19, 2022 NPUB
PUBLISHED FOR OPPOSITION
Apr 19, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 30, 2022 NONP
ASSIGNED TO LIE
Mar 15, 2022 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 11, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 11, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 11, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 11, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 11, 2022 CNEA
ASSIGNED TO EXAMINER
Mar 1, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 18, 2022 NWOS
NEW APPLICATION ENTERED
Feb 17, 2022 NWAP